精子相关抗原9在卵巢浆液性上皮肿瘤中的表达

Expression of SPAG9 in patients with serous epithelial ovarian tumors

目的检测精子相关抗原9(SPAG9)在卵巢浆液性上皮肿瘤中的表达,初步探讨其在卵巢浆液性上皮肿瘤术前诊断中的意义。方法应用免疫组织化学SP法,检测良性组24例、交界性组27例、恶性组32例中SPAG9的表达,采用酶标记免疫吸附测定法(ELISA)检测卵巢浆液性上皮肿瘤患者血清中SPAG9的表达水平,与对应的血清CA125表达水平进行相关性分析,并用受试者工作特征(ROC)曲线评价两指标的诊断价值。结果①SPAG9在卵巢上皮性恶性肿瘤组织中的表达高于交界性组及良性组,并与恶性肿瘤的细胞分化程度相关(P<0.05);②卵巢浆液性上皮性肿瘤患者血清中SPAG9有表达,恶性组高于良性组,其血清学水平与CA125呈正相关(P<0.01),ROC曲线分析提示SPAG9对卵巢上皮性恶性肿瘤有较高的诊断意义,但并不优于CA125。结论SPAG9的表达与卵巢上皮性肿瘤的恶性程度相关,在卵巢上皮性恶性肿瘤中表达较高,可作为卵巢上皮性肿瘤术前诊断和术后治疗监测新的生物学指标。

Objective To investigate tissue expression and serum level of perm-associated antigen SPAG9 in serous ovarian tumors, and explore its diagnostic significance. Methods Expression of the SPAG9 protein was retrospectively detected in paraffin sections from 24 benign epithelial ovarian tumors, 27 borderline serous epithelial ovarian tumors, and 32 serous ovarian carcinomas by immunohistochemistry. Enzyme-linked immunosorbent assay （ELISA） was used to detect the level of serum SPAG9 in patients with epithelial ovarian tumors, and the correlation between serum levels of SPAG9 and CA125 was analyzed. Clinical values of SPAG9 and CA125 were evaluated by the receive operating characteristic （ROC） curve. Results （1）Expression of SPAG9 in serous ovarian carcinomas was obviously higher than that in benign and borderline serous tumors. And it was associated with the grade of tissue differentiation （ P 〈 0.05 ）. （2） The serum SPAG9 level in serous ovarian carcinomas was statistically higher than that in benign epithelial ovarian tumors. In addition, statistical analysis showed a positive correlation with serum levels of SPAG9 and CA125 （P 〈 0.01 ）. The ROC curve revealed that SPAG9 had a significant value in the diagnosis of serous ovarian carcinomas, while it was not preferable to CA125. Conclusion SPAG9, highly expressed in serous ovarian carcinomas, is posi- tively associated with the grade of malignancy. It may serve as a new biological marker for early diagnosis and post-operative treatment of epithelial ovarian tumors.